UM Ventures Investments - NEW
Abiomed Acquires Breeth, a UM Ventures, Baltimore Investment Portfolio Company
Breethe was developing a wearable, portable blood pump oxygenator to function as an artificial lung system for patients suffering from respiratory failure and cardiopulmonary collapse. It was the fourth UM Ventures, Baltimore-backed startup to have a successful exit via acquisition.
University of Maryland Ventures, Baltimore invests in UMB startups based on innovative technologies with promising commercial potential.
We also work closely with our startups to help expand and accelerate new business ventures. Our experienced business development team helps guide the development of go-to-market strategies and business plans, forms management teams, and identifies and helps secure funding.
Investment Portfolio
$1.4M
Invested
16
Investments
$26.3M
Co-Funding
$47.4M*
Follow-on Capital
$14.1M
Awarded Grants
$87.8M
Total Capital
*Excludes capital received by shareholders from acquisitions
Portfolio Company Exits
$20B average market capitalization of acquirer at time of acquisition
14X
Direct investment and common shares from license
5X
Preferred shares from direct investment
Living Pharma
Acquired by Lentigen Technology Inc, a subsidiary of Miltenyi Biotech GmbH
July 2017
Harpoon Medical
Acquired by Edwards Lifesciences
$100M cash and $150M milestones
December 2017
SurgiGYN
Acquired by a Strategic Partner
February 2020
Breethe
Acquired by Abiomed
April 2020
Portfolio Companies and Investments
-
Medcura
A clinical-stage medical device company developing advanced hemostatic and wound treatment products. In 2019, Medcura received FDA Breakthrough...
-
SurgiGyn, Inc.
Acquired by a Strategic PartnerSurgiGYN is developing the uterine electrosurgical device (UED) to improve the safety and ease of total laparoscopic hysterectomy.
-
NeoProgen, Inc.
A preclinical stage company developing a novel cell-based therapy for cardiovascular disease, NeoProgen completed a $1.5M seed funding round.
-
Gliknik Inc.
Gliknik is an immunology company creating and advancing biologic drugs for patients with cancer and autoimmune disorders.
-
Living Pharma, Inc.
Living Pharma develops Personalized CAR T Cell Therapy™. In 2017, 18 months after forming, Lentigen Technology, Inc. acquired Living Pharma.
-
Breethe, Inc.
Breethe is working to develop and commercialize the world's first wearable artificial lung. Breethe was acquired by Abiomed in April 2020.
-
CoapTech
Developing the first FDA-cleared, ultrasound-based solution for feeding tube placement, CoapTech recently received a $1.2M NIH grant.
-
Protaryx Medical
Protaryx is reimagining access to the left atrium for transcatheter cardiac procedures, and raised an $8.3M Series A round led by Ajax Health.
-
NextStep Robotics
This early-stage company developing a personalized robotic therapy for recovering stroke patients was awarded a $1M NIH Cooperative Agreement.
-
Isoprene Pharmaceuticals
Isoprene Pharmaceuticals is an early-stage small molecule oncology company developing oral therapeutics for triple negative breast cancer and other...
-
Harpoon Medical
A minimally invasive, image guided surgical tool for beating heart mitral valve repair. Acquired in 2017 by Edwards Lifesciences for $100 million.